Mannose-binding proteins derived from several plants (i.e. *Hipppeastrum* hybrid and *Galanthus nivalis* agglutinin) or prokaryotes (i.e. cyanovirin-N) inhibit human immunodeficiency virus (HIV) replication and select for drug-resistant viruses that show profound deletion of N-glycosylation sites in the GP120 envelope (Balzarini, J., Van Laethem, K., Hatse, S., Vermeire, K., De Clercq, E., Peumans, W., Van Damme, E., Vandamme, A.-M., Bolmstedt, A., and Schols, D. (2004) *J. Virol.* 78, 10617–10627; Balzarini, J., Van Laethem, K., Hatse, S., Froeyen, M., Van Damme, E., Bolmstedt, A., Peumans, W., De Clercq, E., and Schols, D. (2005) *Mol. Pharmacol.* 67, 1556–1565). Here we demonstrated that the N-acetylglucosamine-binding protein from *Urtica dioica* (UDA) prevents HIV entry and eventually selects for viruses in which conserved N-glycosylation sites in GP120 were deleted. In contrast to the mannose-binding proteins, which have a 50–100-fold decreased antiviral activity against the UDA-exposed mutant viruses, UDA has decreased anti-HIV activity to a very limited extent, even against those mutant virus strains that lack at least 9 of 22 (~40%) glycosylation sites in their GP120 envelope. Therefore, UDA represents the prototype of a new conceptual class of carbohydrate-binding agents with an unusually specific and targeted drug resistance profile. It forces HIV to escape drug pressure by deleting the indispensable glycans on its GP120, thereby obligatorily exposing previously hidden immunogenic epitopes on its envelope.

The glycoproteins GP120 and GP41 that are present on the envelope of HIV mediate the entry of the virus into its host cells. The envelope glycoproteins bind sequentially to the cellular receptor protein CD4 and a co-receptor, mainly CXCR4 or CCR5. The receptor-binding events trigger conformational changes in the GP120 and GP41 that lead to membrane fusion and virus entry. After infection, the host cell synthesizes the viral envelope glycoproteins encoded by the HIV *env* gene. The *env* precursor becomes N-glycosylated to form the GP160 glycoprotein by addition of preassembled GlcManGlcNAc entities in the rough endoplasmic reticulum. After oligomerization to a trimer, GP160 is cleaved in the Golgi apparatus by a cellular protease (leading to noncovalently linked GP120 and GP41), and then the glycans are further processed (3). A large fraction of the predicted accessible surface of GP120 in the trimer is composed of heavily glycosylated structures that surround the receptor-binding regions (4). In GP120 of HIV-1(IIIb), all 24 potential N-linked glycosylation sites are utilized as follows: 13 sites containing complex-type oligosaccharides and 11 sites containing hybrid and/or high mannose-type structures, respectively (5, 6). In GP41, there are seven potential N-glycosylation sites but only four of them seem to be glycosylated. All N-linked glycoprotein carbohydrates in GP120 share a common pentasaccharide ManGlcNAc linked to the amide nitrogen of asparagine through the reducing hydroxyl group of GlcNAc. In HIV-1 GP120, 33% of the oligosaccharides are of the high mannose type, 4% are of the hybrid type, and 63% are of the complex type, being predominantly (~90%) fucosylated and/or sialylated (7, 8).

Several high mannose-binding proteins interact with the HIV GP120 envelope. Indeed, the HIV-1 GP120 is a potential site of attack by the innate immune system through the C-type mannose-binding lectin (MBL) (9). MBL is found as multimers in serum (10) with a subunit molecular mass of 31 kDa. It has been shown that MBL binds to the abundantly present high mannose glycans on GP120 (11). Therefore, MBL represents an important mechanism for recognition of HIV by the immune system. Another human mannose-binding lectin is DC-SIGN present on dendritic cells (12, 13). It functions in dendritic cell recognition and mediates uptake of pathogen leading to antigen presentation to T-cells (14). The neutralizing 2G12 monoclonal antibody (mAb) is also known to be directed to an epitope on GP120 containing N-linked N-acetylgalcosamine/mannose glycans (4, 15). More specifically, the highly conserved Asn-295, Asn-332, and Asn-392 in GP120 have been identified to be involved in 2G12 binding, whereas the Asn-339 and Asn-360 glycans also seem to influence the antibody binding (16). The crystal structure of 2G12 bound to Man₉GlcNAc₂ and α(1,2)Man oligomers is available (17). In particular, the α(1,2)Man residues of the GP120 glycans are important for 2G12 mAb binding to its targeted glycosylation sites (18). The 11-kDa protein cyanovirin-N (CV-N) from the cyanobacterium *Nostoc ellipsosporum* (19) is also specific for α(1,2)mannose oligomers and inhibits HIV by binding to GP120 (20–22). Among the plant lectins, mannose-binding proteins derived from a variety of monocotyledonous species (including GNA, HHA, concanavalin A, and several others) are known to bind the HIV glycoprotein GP120. They show pronounced anti-HIV activity in cell culture presumably by preventing the virus from entering the cells (Refs. 23–28 and for a review see Refs. 29 and 30). Most interestingly, the N-acetylglu-
cosamine-recognition protein from the stinging nettle *Urtica dioica* (UDA) has also been shown to inhibit HIV in cell culture (27) and represents the only GlcNAc-recognition agent that shows a pronounced anti-HIV activity reported so far. UDA is an 8.5-kDa monomeric protein having two carbohydrate-binding sites with different affinities (31). It ranks among the smallest plant lectins ever reported (32, 33).

We demonstrated recently (1, 2) that mannose-binding proteins such as GNA, HHA, and CV-N select for mutant HIV-1 strains that contain deleted N-glycosylation sites in GP120 resulting in different degrees of resistance to the mannose-binding proteins. Because(GlcNAc)₂ is invariably present in all glycans of GP120, it would be of particular interest to investigate the inhibitory effect of the GlcNAc-binding UDA plant lectin against the mannose-specific plant lectin-resistant virus strains, to select for UDA resistance development against wild-type HIV-1, and to phenotypically and genotypically characterize such UDA-resistant viruses. We found that UDA also selects for deletions of N-glycosylation sites of GP120, but surprisingly, its antiviral activity was much more preserved against the mutated virus strains than that of the mannose-specific plant lectins, CV-N and the mAb 2G12. Given the numerous observations that deletion of glycosylation sites in HIV GP120 results in a higher susceptibility of these viruses to the neutralizing activity of antibodies (34–36), and the *in vivo* findings that SIV strains containing deletions in envelope glycosylation sites trigger the production of neutralizing antibodies resulting in markedly lower circulating SIV levels in Rhesus monkeys (37), we believe that we now can put forward an entirely new concept for therapeutic HIV treatment. This work represents the demonstration that carbohydrate-binding agents (CBA), in particular GlcNAc-binding compounds, are a novel and unique class of antivirals endowed with a highly specific and targeted resistance profile. CBAs can force HIV to delete highly conserved glycosylation sites in GP120.

**EXPERIMENTAL PROCEDURES**

**Test Compounds**—The mannose-specific plant lectins from *Galanthus nivalis* (GNA), *Hippeastrum* hybrid (HHA), *Narcissus pseudonarcissus* (NPA), *Cymbidium* hybrid (CA), *Listera ovata*, *Epipactis helleborine* and UDA were derived and purified from these plants, as described before (38–41). AMD3100 was from AnorMed (Langley, British Columbia, Canada), and dextran sulfate-5000 and polyvinylacryl sulfate were from Sigma and Dr. Góroég (Budapest, Hungary), respectively. T20 (pentafuside, enfuvirtide) was kindly provided by AIDS Research Laboratories, Inc., Gaithersburg, MD, and their co-receptor use (R5 or X4) was determined by us on the astroglioma U87.CD4 cell line transfected with either CCR5 or CXCR4 as described previously (42). The following clinical isolates were included in the study: UG273 (clade A, R5), US2 (clade B, R5), ETH2220 (clade C, R5), UG270 (clade D, X4), ID12 (clade E, R5), BZ163 (clade F, 5R), BCF-DIOUM (clade G, R5), BCF06 (clade O, X4), and HIV-2 BV-5061W (X4).

Antiviral testing of these isolates in PBMC was as follows. PBMC from healthy donors were isolated by density gradient centrifugation and stimulated with PHA at 2 μg/ml (Sigma) for 3 days at 37 °C. The PHA-stimulated blasts were washed twice with phosphate-buffered saline and counted by trypan blue. The cells were then seeded at 0.5 × 10⁶ cells per well into a 48-well plate containing varying concentrations of compound in cell culture medium (RPMI 1640) containing 10% fetal calf serum and interleukin-2 (25 units/ml, R & D Systems Europe, Abingdon, UK). The virus stocks were diluted in medium and added at a final dose of 250 pg of p24 per well as determined by a viral core antigen (Ag)-specific enzyme-linked immunosorbent assay. Cell supernatant was collected at day 12, and HIV-1 core Ag in the culture supernatant was analyzed by a p24 Ag enzyme-linked immunosorbent assay kit (PerkinElmer Life Sciences). For HIV-2 p27 Ag detection, the INNOTEST from Innogenetics (Temse, Belgium) was used.

**Genotypering of the HIV-1 Env Region**—Proviral DNA was extracted from cell pellets using the QIAamp blood mini kit (Qiagen, Hilden, Germany) as described recently (43). Both the GP120 and GP41 genes were covered in this assay.

**Viral Load Determination**—The p24 antigen was determined using the commercial assay kit from PerkinElmer Life Sciences.

**RESULTS**

Selection and Genotypic Characterization of UDA-resistant HIV-1 Strains—HIV-1(IIIb) Strains—HIV-1(IIIb)-infected CEM cell cultures were exposed to UDA at ~5 μg/ml (~0.6 μM), which is an ~2–4-fold higher concentration than its EC₅₀ (Fig. 1). Subcultivations were performed by transferring the virus-infected cell suspensions to fresh prepared CEM cell cultures (ratio ~1:10 to 1:5). Syncytia formation was used as the parameter to estimate virus breakthrough. Only when the giant cell formation was abundantly visible in the drug-exposed, virus-infected cell cultures was the UDA concentration increased stepwise. A substantial number of subcultivations were required before virus breakthrough was observed at higher concentrations than the initial UDA concentration.
At least 60 subcultivations (4 or 5 days/subcultivation) were required before the drug concentration could be increased without loss of the virus from the infected cell cultures. It took up to 80–100 subcultivations (4–9 months) before the virus could replicate in the presence of markedly higher UDA concentrations. The extremely long period required to effect marked virus breakthrough is in contrast to the extensive drug resistance development of NRTIs (i.e., lamivudine, 3TC) (data not shown) and NNRTIs (i.e., nevirapine) that easily select for highly resistant virus strains within 5 or less subcultivations (Fig. 1). Moreover, there is clearly a much higher restricted genetic barrier to achieve UDA-resistant virus strains than to obtain NRTI and NNRTI-resistant virus strains. When UDA is added to the virus-infected cell cultures at con-

*TABLE ONE*

**Glycosylation sites affected in HIV-1(IIIb) GP120 under UDA pressure in CEM cell cultures**

| Glycosylated asparagines in HIV-1(IIIb) GP120 | Mutant HIV-1(IIIb) strains that emerged under escalating UDA exposure | UDA-20 | UDA-25-1 | UDA-50-1 | UDA-15-2 | UDA-50-2 | UDA-100-2 | UDA-200-2 |
|---------------------------------------------|-------------------------------------------------------------------|--------|----------|----------|----------|----------|----------|----------|
| 81*NVT*90                                   | Thr/Ile-90                                                        | Ile-90 | Ile-90   | Ile-90   | Ile-90   | Ile-90   | Ile-90   | Ile-90   |
| 138*NDT*138                                 |                                                                  |        |          |          |          |          |          |          |
| 141*NSS*141                                 |                                                                  |        |          |          |          |          |          |          |
| 154*NC*154                                 |                                                                  |        |          |          |          |          |          |          |
| 161*NIS*161                                 | Asp-160                                                           | Asp-160 |          |          |          |          |          |          |
| 189*NDT*188                                 |                                                                  |        |          |          |          |          |          |          |
| 197*NTS*197                                 |                                                                  |        |          |          |          |          |          |          |
| 238*NTT*238                                 | Thr/Met-232                                                       | Thr/Met-232 | Asp-230 | Asp-230 | Asp-230 | Asp-230 | Asp-230 |
| 239*NNT*239                                 | Ile-236                                                           | Ile-236 | Ile-236 | Ile-236 | Ile-236 | Ile-236 | Ile-236 |
| 250*NVS*250                                 |                                                                  |        |          |          |          |          |          |          |
| 260*NGS*260                                 |                                                                  |        |          |          |          |          |          |          |
| 277*NFT*277                                 |                                                                  |        |          |          |          |          |          |          |
| 289*NGS*289                                 |                                                                  |        |          |          |          |          |          |          |
| 307*NCT*307                                 |                                                                  |        |          |          |          |          |          |          |
| 310*NNT*310                                 | Tyr-301                                                           | Tyr-301 | Tyr-301 | Tyr-301 | Tyr-301 | Tyr-301 | Tyr-301 |
| 333*NIS*333                                 | Asn-334                                                           | Asn-334 | Asn-334 | Asn-334 | Asn-334 | Asn-334 | Asn-334 |
| 337*NNT*337                                 | Asp-339                                                           | Asp-339 |          |          |          |          |          |          |
| 356*NKT*356                                 |                                                                  |        |          |          |          |          |          |          |
| 389*NTT*389                                 |                                                                  |        |          |          |          |          |          |          |
| 397*NST*397                                 |                                                                  |        |          |          |          |          |          |          |
| 400*NNT*400                                 |                                                                  |        |          |          |          |          |          |          |
| 444*NVT*444                                 |                                                                  |        |          |          |          |          |          |          |
| 463*NES*463                                 |                                                                  |        |          |          |          |          |          |          |

*a Amino acid sequence numbering is according to Kwong et al. (44).
*b High mannose type glycosylation sites are indicated by an asterisk. The other glycosylation sites are complex mannose-type (according to Leonard et al. (5)).
*c Mutant HIV-1(IIIb) strains that emerged under stepwise escalating UDA concentrations, starting from 20 to 200 μg/ml. Underlined mutated amino acids represent mutations at the asparagine residues that are part of a glycosylation motif. Not underlined mutated amino acids represent mutations at threonine/serine residues that are part of a glycosylation motif.
*d The 397*NST*397 glycosylation site is deleted in HIV-1(IIIb).
*e The 463*NES*463 glycosylation site does not exist in the HIV-1(IIIb) strain used in our experiments because of the presence of a 463*NGP*465 sequence.
Glycosylation Site Deletions in HIV GP120

FIGURE 2. Mapping of the deleted glycosylation sites in GP120 of HIV-1 strains isolated under escalating UDA concentrations in CEM cell cultures and interaction of UDA with glycans of HIV-1 GP120. The graphs were generated by Bobscript, Molscript, and Raster 3D packages (54–56). Panel A, GP120 (according to Kwong et al. (44)) contains 24 numbered N-glycosylation sites (circles). The N-glycosylation sites that were found to be deleted in any of the seven UDA-exposed virus strains were colored in red. The N-glycosylation sites that were not found mutated were colored in green. Panel B, model of a Man,GlcNAc, moiety (green/red ball representation) bound to GP120 (red/brown) at Asn-289 and sandwiched by two UDA molecules in yellow (left) and in blue (right). The two UDA molecules clamp a sequence of two GlcNAc residues and one Man residue. The model is created starting from the x-ray structure of GP120 in Protein Data Bank entry 1gc1 (38), a complex of tri-N-acetylchitotriose sugar with UDA in Protein Data Bank entry 1ehh (32), and a high mannose sugar tree (Man9GlcNAc2) from Protein Data Bank entry 1op5 (17). The GlcNAc-92 sugar next to Trp B21 in 1ehh was fit onto the GlcNAc sugar bound to Asn-289 of GP120. The GlcNAc was allowed to rotate around the bonds connecting it to Asn-289 of GP120 to ensure lack of any clashes between GP120 and the UDA proteins. The original GlcNAc attached to Asn-289 was then removed. In a following step the Man3 residue of the mannose sugar tree was fitted onto residue GlcNAc-90 in code 1ehh (next to Trp A69 of UDA). The GlcNAc-90 was then removed. Finally, all dihedral angles connecting the mannose residues in the carbohydrate tree were manually rotated to remove atomic overlaps with the UDA molecules. Panel C, molecular structure of the UDA carbohydrate interaction for two UDA molecules with the GlcNAc,Man (yellow) oligomer. The remaining Man residues in the high mannose glycan are colored green. The individual carbohydrate rings of the GlcNAc,Man are designated 1, 2, and 3. The amino acids from UDA that interact with GlcNAc,Man are shown in gray. A denotes the interacting amino acids of the first UDA molecule, and B denotes the interacting amino acids from the second UDA molecule.

concentrations as low as 25 μg/ml (selection series-1) or 15 μg/ml (selection series-2) resulted in the appearance of virus isolates that contained at least 9 (7 pure and 2 mixtures with wild-type (series-1)) or 5 (4 pure and 1 mixture with wild-type (series-2)) deletions at potential N-glycosylation sites in GP120. A further stepwise increase of the UDA concentration in the cell cultures resulted in the isolation of virus strains containing eight different glycosylation site deletions in the series-1 of drug exposure. The recovery of virus strains in the series-2 of drug exposure contained nine different glycosylation site deletions that differed slightly from those found in the series-1 of drug exposure (TABLE ONE). The virus strain that was used to start the UDA resistance selections contained 22 of the 24 potential glycosylation sites reported by Kwong and co-workers (44). In total, 11 of 22 glycosylation sites of HIV-1(IIIb) GP120 have been affected by prolonged UDA exposure in cell culture. These mutations represent 7 of 11 high mannose- or hybrid-type and 4 of 11 complex mannosetype glycosylation sites in the GP120. Most interestingly, in GP41, it was observed that a novel N-glycosylation site appeared by mutating Lys to Asn at amino acid position...
126 in the HIV-1 strains UDA-50-2, UDA-100-2, and UDA-200-2 and in the virus strains UDA-25-1 (mixture with wild-type) and UDA-50-1.

Mapping of the UDA-selected Amino Acid Mutations in the Threedimensional Structure of HIV-1 GP120—The N-glycosylation sites that were deleted under UDA drug pressure were mapped on the threedimensional structure of GP120 determined by Kwong et al. (44) (Fig. 2). It shows the 24 putative glycosylation sites represented by circles and their accompanying amino acid number. The red circles in Fig. 2 indicate the N-glycosylation site deletions that emerge under UDA drug treatment in all isolates. As can be seen, the deleted glycosylation sites occur scattered rather than clustered at certain positions in GP120. Although Asn-88, Asn-230, and Asn-234 are closely located at the GP41-binding interface of GP120, the other deleted glycosylation sites were located between the V1 and V2 domains (Asn-160), in the V3 region (Asn-301), closely near the V3 domain (Asn-289 and Asn-332), and in the V4 domain (Asn-392 and Asn-406). The Asn-448 glycosylation site is located between C4 and V5 (5).

Drug Sensitivity/Resistance Spectrum of the Mutated Virus Strains—The mutant virus strains isolated at different time points during the UDA selection process have been phenotypically characterized for their susceptibility to the inhibitory potential of the N-acetylgalcosaminempecific UDA; the α(1,3)/α(1,6)-mannose-specific plant lectin HNA, GNA, L. ovata, NPA, CA, and E. helloborigine; the α(1,2)-mannose-specific prokaryotic CV-N; the polyanions DS-5000 and polyvinylacryl sulfate; the CXCR4 antagonist AMD3100; and the GP41-targeting fusion peptide T-20 (TABLE TWO). The HIV-1/UDA-20 strain virtually displays a similar drug sensitivity spectrum as wild-type virus. For all other mutant virus strains, UDA showed a modestly decreased inhibitory activity (with one exception, only 3–12-fold). In contrast, although the α(1,3)/α(1,6)-mannose-specific plant lectins had an 10–30-fold decreased antiviral activity against the HIV-1/UDA-15-2 virus strain that contains five deletions in the glycosylation sites of GP120, they invariably lost 40–200-fold of their antiviral potency against the other virus strains that contained nine deleted glycosylation sites. Also the α(1,2)-mannose-binding cyanovirin showed (except for the HIV-1/UDA-15-2 strain) a 50–100-fold decreased antiviral activity, which was fairly comparable with the loss of antiviral activity of the mannose-specific plant lectins (TABLE TWO). Also, the mAb 2G12 markedly lost antiviral activity against the UDA-exposed viruses. In sharp contrast, none of the other entry inhibitors, affecting three different sites of interaction in the entry process (i.e. GP120 for the polyanions, CXCR4 for AMD3100 and GP41 for T20), showed a significantly decreased antiviral activity against the mutant virus strains selected in the presence of escalating UDA concentrations (TABLE TWO).

Inhibitory Activity of UDA against HIV-1(IIIb) Isolates Selected under Escalating Concentrations of Mannose-binding Proteins—Recently, a variety of HIV-1(IIIb) strains has been selected under escalating concentrations of the mannose-binding plant lectins GNA and HNA. The locations of the deleted glycosylation sites in GP120 have been determined (1, 2). The number of GP120 glycosylation sites in GP120 affected in the virus isolates ranked from 2 (isolate 2) to 8 (isolates 10 and 12) (TABLE THREE). The degree of decreased sensitivity of these viruses against the inhibitory activity of the mannose-binding HNA and GNA closely correlated with an increasing number of deleted glycosylation sites in HIV-1 GP120. The decreased inhibitory activities of HNA and GNA amounted to 600–700-fold for the highest mutated virus strains (isolate 12) (TABLE THREE). In sharp contrast, the sensitivity of the virus strains for UDA were at most 1.5–2.5-fold decreased for the highest mutated virus strains, but in the majority of cases, UDA fully kept its antiviral potency against the mutant virus strains (TABLE THREE).

Inhibitory Activity of UDA and Mannose-binding Proteins against Isolates of Distinct HIV-1 Clades Containing Varying Numbers of Glycosylation Sites in GP120—UDA and also the mannose-specific GNA, HNA, CA, and CV-N were evaluated for their inhibitory activity against the replication of virus strains that belong to different HIV-1 clades (TABLE FOUR). The mannose-specific compounds showed widely varying degrees of inhibitory activities against the different clade isolates. The α(1,2)-mannose-binding CV-N kept a much more consistent antiviral potency than the mannose-specific plant lectin congeners (EC50 range between 0.15 and 1.8 μg/ml) (0.013–0.16 μM) (TABLE FOUR), but still showed up to 12-fold variation in its EC50 values. Remarkably, UDA kept a consistent antiviral inhibitory potential irrespective of the nature of the HIV clade (EC50 range between 4.9 and 8.9 μg/ml) (0.56–10 μM) (TABLE FOUR).
Glycosylation Site Deletions in HIV GP120

in the absence of UDA, no marked differences were observed in the replication kinetics of HIV-1/UDA-200-2 and wild-type HIV-1 (followed for 4 days after which full cytopathicity was observed). In contrast, HIV-1/UDA-50-1 showed a 2–3-fold lower p24 production, compared with wild-type HIV-1 at all time points evaluated (data not shown). Moreover, an HIV-1/UDA-200-1 strain that was isolated at the end of the UDA drug selection series-1 was heavily compromised in its replication and infection efficacy. This resulted in a very poor p24 viral replication kinetics of HIV-1/UDA-200-2 and wild-type HIV-1 (fol-

TABLE THREE

| N-Glycosylation sites affected in GP120 | Mutated HIV-1(IIIb) strain$^a$ |
|---------------------------------------|---------------------------------|
| 1 | 2 | 3 | 5 | 7 | 9 | 8 | 6 | 4 | 11 | 10 | 12 |
| 88 | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− |
| 186 | + | + | + | + | + | + | + | + | + | + | + |
| 230 | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− |
| 234 | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− |
| 276 | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− |
| 289 | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− |
| 295 | + | + | + | + | + | + | + | + | + | + | + |
| 301 | + | + | + | + | + | + | + | + | + | + | + |
| 322 | | | | | | | | | | | |
| 339 | + | + | + | + | +/− | +/− | +/− | +/− | +/− | +/− | +/− |
| 386 | + | + | + | + | + | + | + | + | + | + | + |
| 392 | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− | +/− |

$^a$ N-Glycosylation sites in GP120 were deleted in the mutant HIV-1 strains with +. The +/− means that DNA sequencing revealed a mixture between wild-type and mutated(deleted) glycosylation site.

$^b$ Mutant HIV-1 strains that were isolated under escalating concentrations of the mannose-binding proteins GNA and HHA are shown. The isolation and characterization of the virus strains were described by Balzarini et al. (1, 2). The code numbers correspond to following designations in the references as follows: 1, wild type; 2, GNA-1.0; 3, HHA-1.1; 4, HHA-2.1; 5, GNA-1.1a; 6, HHA-1.3; 7, GNA-2.1a; 8, HHA-2.2; 9, GNA-1.2; 10, GNA-500CS; 11, HHA-500CS; and 12, HHA-500SN.

$^c$ 50% effective concentration of the antiviral agents in CEM cell cultures is shown.

$^d$ Data were taken from Balzarini et al. (1, 2) (µg/ml values converted to µM values).

TABLE FOUR

| Compound | EC$_{50}^a$ (µM) in CEM cell cultures |
|----------|--------------------------------------|
| GNA      | 0.008 0.020 0.056 0.24 0.58 0.98 0.62 0.40 0.11 3.1 0.52 5 |
| HHA      | 0.006 0.024 0.040 0.20 0.52 0.74 0.38 0.22 0.12 2.1 1.1 3.8 |
| UDA      | 0.129 0.141 0.18 0.21 0.19 0.21 0.15 0.18 0.11 0.18 0.29 0.16 |

$^a$ EC$_{50}^a$ is the concentration required to inhibit viral p24 (for HIV-1) or p27 (for HIV-2) production by 50%.

$^d$ 50% effective concentration or compound concentration was required to inhibit viral p24 (for HIV-1) or p27 (for HIV-2) production by 50%.

$^d$ Data were obtained in CEM cell cultures.

| Compound | HIV-1 clade isolate (with co-receptor preference) | HIV-2 | HIV-1 laboratory strains |
|----------|-----------------------------------------------|-------|-------------------------|
| A, UG273 | 0.97 0.56 1.0 1.0 0.62 0.61 1.0 1.0 | U504 | 0.052 0.56 1.0 |
| B, US2 | 0.58 0.11 0.88 0.98 0.24 0.09 0.82 0.024 | BV-5061W | 0.022 0.072 0.12 |
| C, ETH2220 | 0.54 0.34 2.0 0.4 0.38 0.50 2.0 0.38 | X4 | 0.066 0.028 0.13 |
| D, UG270X | 0.44 0.23 0.96 0.42 0.096 0.50 0.74 0.26 | NL4.3 | 0.029 0.018 0.19 |
| E, ID12R | 0.13 0.038 0.16 0.03 0.10 0.10 0.077 0.013 | Bal | 0.002 0.014 0.16 |

$^a$ 50% effective concentration or compound concentration was required to inhibit viral p24 (for HIV-1) or p27 (for HIV-2) production by 50%.

$^d$ Data were obtained in CEM cell cultures.

DISCUSSION

A pre-assembled glycan entity consisting of two GlcNAc, nine man-

nose, and three glucose molecules (Glc$_3$Man$_{2}$GlcNAc$_2$) (5, 45) is linked on the amide function of asparagines in GP120 through a β1 linkage with the terminal GlcNAc. However, extensive modifications of
the N-linked oligosaccharides are performed as soon as the glycan block has been added to the target protein, contributing to the heterogeneity of the resulting glycoproteins (3). The HIV envelope GP120 is among the most heavily glycosylated proteins known. Up to 50% of the 120-kDa molecular mass of GP120 consists of N-linked carbohydrates. In particular, HIV GP120 contains 20–29 N-glycosylation sites depending on the nature of the viral isolate and the type of virus clade. However, a number of these sites are very well conserved among all clades. We calculated the level of conservation of the different glycosylation sites in GP120 of a wide variety of HIV clade isolates (consensus sequences) (Fig. 3). At least 11 (out of 24) N-glycosylation sites that are found in HIV-1(IIIB) GP120 were fully conserved, and 4 additional N-glycosylation sites were conserved in 95% of the consensus strains. Thus, almost 50% of the total number of N-glycosylation sites found in HIV-1(IIIB) GP120 were fully conserved among all HIV-1 clades. Sixteen percent of the glycosylation sites in HIV-1(IIIB) GP120 (4 of 24) were conserved in 95% of the virus strains. It is important to notice that more than one-third of the fully conserved N-glycosylation sites were deleted in the UDA-resistant virus strains that were isolated during the two independent series of UDA-1 and UDA-2 drug selections (Asn-88, Asn-160, Asn-301, and Asn-392). Also, 2 of 4 (50%) of the N-glycosylation sites that showed 95% conservation were deleted in the UDA-resistant virus strains (Asn-234 and Asn-448). It thus seems that almost half of the N-glycosylation sites that are highly conserved (>95%) among all subtypes of clinical HIV-1 isolates can be deleted under UDA pressure (also see Fig. 2 for a three-dimensional view of the deleted N-glycosylation sites in GP120). Most interestingly, these deletions occur almost at the very beginning of the UDA exposure period and remain deleted during the whole drug selection process (TABLE ONE). Given the fact that these glycosylation sites are among the most conserved in GP120, hiding underlying amino acid epitopes of GP120 by these glycans seems very crucial for the virus to maintain its in vivo virulence and/or to effectively protect the underlying amino acid epitopes against the neutralizing activity of the immune system. The resistance selection experiments in this study have been performed with the laboratory HIV-1(IIIb) strain. However, we also selected for resistance of the clinical HIV-1/HE isolate against the plant lectin GNA in CEM cell cultures (2). As found for the HIV-1(IIIb) resistance selection experiments, the glycosylation pattern of GP120 of the drug-exposed clinical virus isolate was also affected (2). Also, resistance to UDA slowly arises after the clinical HIV-1/HE isolate had been exposed to the drug for at least 20 subcultivations. Thus, it seemed that primary HIV-1 isolates may adapt in the same way as the laboratory HIV-1(IIIb) strain to the plant lectin pressure.

Wei et al. (46) and others have demonstrated that HIV-1 continuously changes its glycan shield to escape the immune system in virus-infected individuals to avoid neutralization. Moreover, a variety of studies has shown that deletion of one or several glycosylation sites in HIV-1 GP120 results in a markedly higher susceptibility of these viruses to the neutralizing activity of antibodies (34–36). It is therefore very likely that forcing the virus to remove these glycans from its envelope GP120 by mutating the glycosylation sites under selective pressure of UDA may
compromise survival of the virus in the presence of an active immune surveillance. Strong evidence that a deleterious effect of the immune system on deglycosylated virus strains does also occur in vivo is provided by Reitter et al. (37), who infected Rhesus monkeys with SIV strains that contained mutations at a few (two) glycosylation sites in its envelope glycoprotein. Such infection resulted in formation of higher titers of neutralizing antibodies directed against the previously hidden epitopes at the deglycosylated region of the env glycoprotein. It also resulted in substantially lower levels of circulating mutant SIV in the plasma of these animals. It is clear that the highly dense carbohydrate shield on GP120 causes a relatively low antigenicity and low immunogenicity of GP120 and protects the virus against the immune system (37, 47, 48). These results demonstrate a crucial role for N-linked glycosylation in limiting the neutralizing antibody response to SIV and in shielding the virus from immune recognition. As a consequence, it is also evident that the virus needs a minimum degree of glycans on its GP120 to avoid an efficient antibody response against silent (protected) areas on GP120. Pressure of a drug like UDA on the virus would necessarily lead to sequential deletion of an increasing amount of glycosylation sites in GP120. These events would result in not only an increased exposure of the viral envelope to a detrimental antibody response but eventually also to a lesser infectivity (virulence) of the virus. We indeed found that an HIV-1 strain that was selected in the presence of escalating UDA concentrations, and that was isolated from a virus pool lacking at least eight to nine glycosylation sites in the GP120, markedly lost its infectious potential. Another highly mutated HIV-1 strain was also shown to have a lower replication potential.

Our findings indicate that CBAs such as N-acetylgalactosamine-binding compounds may delete glycosylation sites in its GP120 envelope in an attempt to escape the CBA pressure. However, such virus strains may become increasingly vulnerable to a more efficient suppression/neutralization by the immune system and increasingly less infectious (virulent) for the host cells. In addition, a lower efficiency of virus transmission may also occur because of the fact that the innate DC-SIGN and mannose-binding lectin that bind the HIV particles by adhering through the mannose residues of the HIV GP120 glycans before transmitting and exposing the virus to T-lymphocytes will markedly lose their HIV binding capacity and transmission because of selective and progressive glycan depletion in GP120.

Leonard et al. (5) have demonstrated that all 24 N-linked glycosylation sites in GP120 of HIV-1(HIV2) are utilized and that 13 of the sites contain complex-type oligosaccharides, although 11 contain hybrid and/or high mannose structures (TABLE ONE). Generally, high mannose-type oligosaccharides typically have 2–6 mannose residues attached to the core pentasaccharide Man₆GlcNAc₂, whereas the complex oligosaccharides have different numbers and types of carbohydrate residues in their outer branches. Hybrid oligosaccharides contain elements of both structures. More importantly, in contrast to the glycoproteins of HIV-1 GP120, mammalian cell surface or serum glycoproteins rarely contain terminal mannose residues (49). Indeed, in mammals, the presence of a terminal mannose moiety on a protein triggers binding to hepatic lectin receptors and fast removal from the plasma (50). However, HIV-1 uses the terminal mannoses to its advantage for reducing its antigenicity against the human immune system (16). It is of interest to note that during the UDA selection process more high mannose/hybrid-type glycan-containing glycosylation sites (7 of 11) were deleted compared with complex mannose-type glycans of GP120 (4 of 11) (TABLE ONE). A similar phenomenon was observed in the virus strains that were selected in the presence of escalating concentrations of mannose-specific GNA and HHA (1, 2). Thus, both the man-

Glycosylation Site Deletions in HIV GP120

nose- and GlcNAc-specific CBAs have a similar preference for annihilation of high mannose-type glycans in GP120.

The 2G12 antibody is one of the few broadly neutralizing antibodies directed against HIV-1. It recognizes an epitope around the C4/V4 region of GP120 with nanomolar affinity (4, 15, 18). Except for one clade, it neutralizes a wide spectrum of different HIV-1 isolates from all known virus clades (15, 51). Very recently, it was shown that administration of 2G12, together with two other neutralizing antibodies, was able to delay virus rebound in HIV-1-infected individuals after termination of antiretroviral therapy. However, it was also shown in the same study that the eventual appearance of virus under 2G12 treatment proved to have lost its sensitivity to 2G12 (52). 2G12 likely binds to the high mannose-type residues in a highly conserved epitope containing Asn-295, Asn-332, and Asn-392 (4, 18, 53). The Asn-339 and Asn-386 glycans may indirectly influence 2G12 binding. Not surprisingly, 2G12 markedly or even completely lost its inhibitory activity against the HIV-1 strains that emerged under UDA treatment and in which the Asn-332 and Asn-392 glycosylation sites were deleted. In contrast, these virus strains only marginally lost their sensitivity to the inhibitory effect of UDA. Thus, neutralizing antibodies such as 2G12, whose sugar-recognition epitopes consist of at most 2–3 spatially and closely located glycan sites, are easily vulnerable to loss of neutralizing activity upon mutation of one or two glycans of these sites, although sensitivity to UDA is virtually not affected by a few glycosylation site deletions because this compound is thought to be bound at numerous sites of GP120. This is also shown for the α(1,2)-mannose-binding CV-N that lost marked inhibitory activity against virus strains that have deleted glycosylation sites at Asn-332, Asn-339, and Asn-448 in their GP120 envelope protein (2). Consequently, (neutralizing) antibody epitopes represent relatively small and specific areas on GP120 that can be easily mutated (i.e. by the evolving glycan shield). Glycan deletions in this area of GP120 may then result in significant loss of neutralizing activity of the envelope antibodies. The GlcNAc-binding UDA needs a much higher number of glycan deletions before significant loss of antiviral activity. The equal antiviral effectiveness of UDA, irrespective of the nature of the clade, is in agreement with our findings of virtual independence of the virus suppression potential of UDA on the number and type of glycosylation sites in GP120. Thus, CBAs like UDA are endowed with a very high genetic barrier in terms of resistance development, and the long duration of virus breakthrough and the very modest loss of sensitivity of HIV to UDA are in agreement with each other.

It is yet unclear why the GlcNAc-binding UDA is endowed with much less variation in its antiviral profile than mannose-binding proteins such as 2G12, the mannose-specific plant lectins, and CV-N. One contributing factor may be the size of the protein. Although the 2G12 antibody has a heavy molecular mass and the plant lectins GNA and HHA consist of tetramers with a molecular mass of 50,000 Da, UDA is a very high genetic barrier in terms of resistance development, and the long duration of virus breakthrough and the very modest loss of sensitivity of HIV to UDA are in agreement with each other.
Glycosylation Site Deletions in HIV GP120

HHA and GNA predominantly recognize α(1,3)- and/or α(1,6)-mannose residues that are particularly located between the surface of the glycans and the top of the pentasaccharide core, UDA represents a compound with an entirely different sugar specificity (GlcNAc profile (31–33). A GlcNAc2 oligomer is invariably present at the basis of the pentasaccharide core in each of the glycosylation sites in GP120. Moreover, in the complex and hybrid mannose-type glycans in GP120 that are present in ~63% of the total average number of glycosylation sites (7, 8), at least one or several additional GlcNAc units can be present. Thus, UDA may have the opportunity to interact with the GP120 glycans not only at each N-glycosylation site on GP120 but even at several locations within each of the GP120-bound oligosaccharides. It is therefore interesting to have a closer look to the crystal structure of UDA (31). It resembles a dumbbell-shape molecule consisting of two domains analogous to hevein and connected to each other by a four-amino-acid sequence. Sugar-binding sites are present at both ends of the UDA molecule. Each domain (~42 amino acids) is approximately double the size of a glycan on GP120. In the crystal complex of UDA with GlcNAc2, one GlcNAc oligomer is sandwiched between two different UDA molecules in a head-to-tail mode, and another GlcNAc oligomer is also sandwiched by the first UDA molecule and second UDA (32). The GlcNAc binding is mainly performed by three aromatic amino acid residues and one serine through hydrogen bonds and amino acid stacking interactions. The binding is quite specific for N-acetylgalactosamine moieties. We hypothesized that, given the relatively low molecular weight of UDA and the flexibility between the two carbohydrate-binding domains in the UDA molecule, it may well be possible that UDA is attached to the GlcNAc moiety of the glycans that link the asparagines of GP120 with the complex/high mannose tree. Our computer-assisted modeling indeed revealed that two UDA molecules can efficiently interact with the GlcNAc2 and the next mannose molecule of the glycans on GP120 (Fig. 2, B and C). Because many UDA molecules may concomitantly interact with GP120, it becomes understandable that a substantial amount of glycosylation sites in GP120 need to be deleted before significant resistance to such a molecule may occur (high genetic barrier). Only a few glycosylation site deletions in GP120 will have a very marginal effect on UDA inhibition of HIV, as demonstrated in our studies. Therefore, GlcNAc-binding agents may represent an advantage over mannose-binding agents.

Because mannose- and also GlcNAc-binding plant lectins may be randomly bound to many N-linked glycosylated (cellular) proteins, potential toxic side effects of GlcNAc-binding agents can be expected. However, it was shown previously that the mannose-specific GNA and HHA lack acute toxicity upon intravenous administration to adult mice at 50 mg/kg (28). We could also ascertain for UDA that it did not afford visible toxic side effects when given intravenously to mice at doses of 5, 10, and 25 mg/kg. It has also been reported that UDA did not agglutinate visible toxic side effects when given intravenously to mice at doses of 5, 10, and 25 mg/kg. It has also been reported that UDA did not agglutinate 10, and 25 mg/kg. It has also been reported that UDA did not agglutinate visible toxic side effects when given intravenously to mice at doses of 5, 10, and 25 mg/kg.

replication and virus clearance from the systemic circulation because of the exposure of previously hidden immunogenic epitopes on GP120. CBAs may therefore represent the first available drugs for which chemotherapy may act in concert with an immunological response. (iii) Although the current drugs are targeted against viral proteins (i.e. reverse transcriptase, protease, GP41) in a stoichiometric manner (one drug molecule binds to one target molecule), several CBA molecules likely bind to each single GP120 molecule of the virus at the same time, resulting in the requirement of multiple mutations (≫5) before decreased drug susceptibility becomes evident (high genetic barrier). Each glycosylation site deletion may result in a specific neutralizing antibody response. The monkey infection experiments of Reitter et al. (37), in which SIV strains were used that contained deleted envelope glycosylation sites, provide strong evidence for the antiviral potential of the CBA concept in vivo. Our findings indicate that the glycosylation of HIV GP120 may be the “Achilles heel” of the virus. Targeting the carbohydrate moieties on HIV GP120 by direct therapeutic intervention with CBAs may represent an entirely new conceptual approach with far-reaching applications, including vaccine development combined with chemotherapy. Such a concerted action between chemotherapy and immune surveillance would thus far be unprecedented in anti-HIV therapy. This concept should be further explored not only for HIV but also for other chronic infections by enveloped viruses that contain heavily glycosylated envelope proteins such as hepatitis B and C viruses and perhaps also for more acute infections by enveloped viruses such as influenza viruses, respiratory syncytial virus, coronaviruses, and several flaviviruses.

Acknowledgments—We are grateful to Ann Absillis, Lizette van Berckelaer, Yoeri Schrooten, Sandra Claes, Rebecca Provinciael, and Eric Fonteyn for excellent technical assistance and Christiane Callebault for dedicated editorial assistance.

REFERENCES

1. Balzarini, J., Van Laethem, K., Hatse, S., Vermeire, K., De Clercq, E., Peumans, W., Van Damme, E., Vandamme, A.-M., Bolostadst, A., and Schols, D. (2004) J. Virol. 78, 10617–10627
2. Balzarini, J., Van Laethem, K., Hatse, S., Froeyen, M., Van Damme, E., Bolostadst, A., Peumans, W., De Clercq, E., and Schols, D. (2005) Mol. Pharmacol. 67, 1556–1565
3. Helenius, A., and Aebi, M. (2001) Science 291, 2364–2369
4. Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A., and Sodroski, J. G. (1998) Nature 393, 705–711
5. Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N., and Gregory, T. J. (1990) J. Biol. Chem. 265, 10373–10382
6. Gallaher, W. R., Ball, J. M., Garry, R. F., Martin-Amedee, A. M., and Montelaro, R. C. (1995) AIDS Res. Hum. Retroviruses 11, 191–202
7. Mizuochi, T., Spellman, M. W., Larkin, M., Solomon, J., Basa, L. J., and Feizi, T. (1988) Biochem. J. 254, 599–603
8. Mizuochi, T., Spellman, M. W., Larkin, M., Solomon, J., Basa, L. J., and Feizi, T. (1988) Biomed. Chromatogr. 2, 260–270
9. Xu, J., Gewurz, H., and Spear, G. T. (2005) Mol. Immunol. 42, 145–152
10. Hansen, S., and Holmskov, U. (1998) Immunobiology 199, 165–189
11. Hart, M. L., Saifuddin, M., Uemura, K., Bremer, E. G., Hooker, B., Kawasaki, T., and Spear, G. T. (2002) AIDS Res. Hum. Retroviruses 18, 1311–1317
12. Alvarez, C. P., Lassala, F., Carrillo, J., Muniz, O., Corbi, A. L., and Delgado, R. (2002) J. Virol. 76, 6841–6844
13. Simmons, G., Reeves, J. D., Grogan, C. C., Vandenbergho, L. H., Barbahou, F., Whitbeck, J. C., Burke, E., Buchmeier, M. J., Saillieux, E. J., Riley, J. L., Doms, R. W., Bates, P., and Pohlmann, S. (2003) Virology 315, 115–123
14. Geijtenbeek, T. B., and van Kooyk, Y. (2003) Curr. Top. Microbiol. Immunol. 276, 31–54
15. Tkola, A., Purscher, M., Muster, T., Ballau, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., and Katinger, H. (1996) J. Virol. 70, 1100–1108
16. Sanders, R. W., Venturi, M., Schiffer, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D., and Moore, J. P. (2002) J. Virol. 76, 7293–7305
17. Calarase, D. A., Scanlan, C. N., Zwick, M. B., Deechongkit, S., Mimura, Y., Kunert, R.,
Glycosylation Site Deletions in HIV GP120

Zhu, P., Wormald, M. R., Stanfield, R. L., Roux, K. H., Kelley, J. W., Rudd, P. M., Dwek, R. A., Katinger, H., Burton, D. R., and Wilson, I. A. (2003) Science 300, 2065–2071

18. Scanlan, C. N., Pantophlet, R., Wormald, M. R., Ollmann Saphire, E., Stanfield, R., Wilson, I. A., Katinger, H., Dwek, R. A., Rudd, P. M., and Burton, D. R. (2002) J. Virol. 76, 7306–7321

19. Boyd, M. R., Gustafson, K. R., McMahon, J. B., Shoemaker, R. H., O’Keefe, B. R., Mori, T., Gulakowski, R. J., Wu, L., Rivera, M. I., Laurencot, C. M., Currens, M. J., Cardellina, J. H., Ii, Buckel, R. W., Jr., Nara, P. L., Pannell, L. K., Soder, R. C., II, and Henderson, L. E. 1997. Antimicrob. Agents Chemother. 41, 1521–1530

20. Mori, T., Shoemaker, R. H., Gulakowski, R. J., Krepps, B. L., McMahon, J. B., Gustafson, K. R., Pannell, L. K., and Boyd, M. R. (1997) Biochem. Biophys. Res. Comm. 238, 218–222

21. O’Keefe, B. R., Shenoy, S. R., Xie, D., Zhang, W., Muschik, J. M., Currens, M. J., Chaiten, I., and Boyd, M. R. (2000) Mol. Pharmacol. 58, 982–992

22. Bolmstedt, A. J., O’Keefe, B. R., Shenoy, S. R., McMahon, J. B., and Boyd, M. R. (2001) Mol. Pharmacol. 59, 949–954

23. Mandal, D. K., Kishore, N., and Brewer, C. F. (1994) Biochemistry 33, 1149–1156

24. Favero, J. (1994) Glycobiology 4, 387–396

25. Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cavan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton, W. A. (1996) Nature 381, 667–673

26. Balzarini, J., Schols, D., Neyts, J., Van Damme, E., Peumans, W., and De Clercq, E. (1991) Antimicrob. Agents Chemother. 35, 410–416

27. Balzarini, J., Neyts, J., Schols, D., Hosoya, M., Van Damme, E., Peumans, W., and De Clercq, E. (1992) Antiviral Res. 18, 191–207

28. Balzarini, J., Hatse, S., Vermeire, K., Princken, K., Aquaro, S., Perin, C.-F., De Clercq, E., Egerink, H., Van den Mooter, G., Peumans, W., Van Damme, E., and Schols, D. (2004) Antimicrob. Agents Chemother. 48, 3858–3870

29. Van Damme, E. J. M., Peumans, W. J., Pusztai, A., and Bardocz, S. (eds) (1998) in Handbook of Plant Lectins: Properties and Biomedical Applications, pp. 1–451, John Wiley & Sons Ltd., Chichester, UK

30. Sharon, N., and Lis, H. (eds) (2003) in Lectins, 2nd Ed., pp. 1–6, Kluwer Academic Publishers Group, Dordrecht, Netherlands

31. Shibuya, N., Goldenstein, I. J., Shafir, J. A., Peumans, W. J., and Broekaert, W. F. (1986) Arch. Biochem. Biophys. 249, 215–224

32. Harata, K., and Muraki, M. (2000) Structure Fold Des. 297, 673–681

33. Saul, F. A., Rovira, P., Boulot, G., Van Damme, E. J. M., Peumans, W., Truffa-Bachi, P., and Bentley, G. A. (2000) Structure Fold. Des. 8, 593–603

34. Back, N. K., Smit, L., De Jong, J. J., Keulen, W., Schutten, M., Goudsmitt, J., and Terstette, M. (1994) Virology 199, 431–438

35. Bolmstedt, A., Hinkula, J., Rowcliffe, E., Biller, M., Wahren, B., and Olofsson, S. (2001) Vaccine 20, 397–405

36. Kang, S. M., Quan, F. S., Huang, C., Guo, L., Ye, L., Yang, C., and Compaïs, R. W. (2005) Virology 331, 20–32

37. Reitter, J. N., Means, R. E., and Destroiers, R. C. (1998) Nat. Med. 4, 679–684

38. Van Damme, E. J. M., Allen, A. K., and Peumans, W. J. (1987) Plant Physiol. 85, 566–569

39. Van Damme, E. J. M., Allen, A. K., and Peumans, W. J. (1988) Physiol. Plant. 73, 52–57

40. Van Damme, E. J. M., Smeets, K., Torrekens, S., Van Leuven, F., and Peumans, W. J. (1994) Eur. J. Biochem. 221, 769–777

41. Van Damme, E. J. M., and Peumans, W. J. (1989) Physiol. Plant. 79, 1–6

42. Schols, D., Struyf, S., Van Damme, J., Esté, J. A., Henson, G., and De Clercq, E. (1997) J. Exp. Med. 186, 1383–1388

43. Van Laethem, K., Schrooten, Y., Lemey, P., Van Wijngaarden, E., De Wit, S., Van Ranst, M., and Vandamme, A.-M. (2005) J. Virol. Methods 123, 25–34

44. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A. (1998) Nature 393, 648–659

45. Earl, P. L., Moss, B., and Doms, R. W. (1991) J. Virol. 65, 2047–2055

46. Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., Komarova, N. L., Nowak, M. A., Hahn, B. H., Kwong, P. D., and Shaw, G. M. (2003) Nature 422, 307–312

47. Olofsson, S., and Hansen, J. E. (1998) Scand. J. Infect. Dis. 30, 435–440

48. Burton, D. R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10018–10023

49. Weis, W. I., and Drickamer, K. (1996) Annu. Rev. Biochem. 65, 441–473

50. Lee, W. R., Syu, W. J., Du, B., Matsuda, M., Tan, S., Wolf, A., Essex, M., and Lee, T. H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2213–2217

51. Tkola, A., Pomales, A. P., Yuan, H., Korber, B., Maddon, P. J., Allaway, G., Katinger, H., Barbac, C. F., Burton, D. R., Ho, D. D., and Moore, J. P. (1995) J. Virol. 69, 6609–6617

52. Tkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leermann, C., Mannique, A., Huber, M., Behr, M., Oenxiu, A., Weber, R., Stiegler, G., Vezlar, B., Katinger, H., Aceto, I., and Günthard, H. F. (2005) Nat. Med. 11, 615–622

53. Zhu, X., Borchers, C., Bieentiw, R. J., and Tomer, K. B. (2000) Biochemistry 39, 11194–11204

54. Enouf, R. (1999) Acta Crystallogr. Sect. D. Biol. Crystallogr. 55, 938–940

55. Kraulis, P. J. (2001) J. Appl. Crystallogr. 24, 946–950

56. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505